Novo Nordisk (NVO.US) rises more than 4% before market open; competitor HIMS cancels low-cost generic weight loss drug plan

K-LinePoet · 2026-02-14T10:03:19+00:00

Novo Nordisk(NVO.US) rose over 4% after competitors Hims&Hers Health canceled their low-cost generic weight-loss drug plans. This news eased market concerns about potential generic drug competition impacting their products. Meanwhile, Novo Nordisk announced a share buyback program of up to 15 billion Danish kroner and filed a lawsuit against Hims, accusing their products of patent infringement.

K-LinePoet

2026-02-14 10:03:19

Abstract generation in progress

On Monday, Novo Nordisk (NVO.US) rose more than 4% in pre-market trading, reaching $49.88. In the news, competitor telemedicine company Hims & Hers Health (HIMS.US) withdrew its plan to launch low-cost generic weight loss drugs due to regulatory and legal pressures. This news significantly alleviated market concerns about Novo Nordisk’s core products facing competition from cheap generics, strengthening its moat in the GLP-1 drug market. Additionally, Novo Nordisk announced the initiation of a share repurchase program with a maximum amount of 15 billion Danish kroner.

In a statement, Novo Nordisk said: “Hims has conducted a series of promotional activities focusing on its combination products, deceiving consumers and healthcare professionals into believing that these unapproved drugs have clinical efficacy and safety.” The company believes these counterfeits “are endangering patients’ health and well-being.” Novo Nordisk stated that it has filed a lawsuit in Delaware, alleging that Hims’ products (including its weight loss injections) are a combination form of semaglutide, thereby infringing on its patents.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.